1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
8Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量:829
5Liaw YF, Gane E, Leung N, et al. 2 Year GLOBE trial resuits; telbivudine Is superior to lamivudine in patients with chronic hepatitis B [J]. Gastroenterology, 2009,136 ( 2 ):486 -495.
8Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore prorooter and precore open reading frame[J]. Virology,1997, 233(2): 374 -81.
9Bridges EG, Selden JR, Luo S. Nonclinical Safety Profile of Telbivudine Novel Potent Antiviral Agent for Treatment of Hepatitis B [ J ]. Antimicro Agents Chemother, 2008, 52 (7): 2521 -2528.
10Milich D, Liang TJ. Exploring the biological basis of hepatitisB eantigen in hepatitis B virus infection [J]. Hepatology, 2003, 38 (5): 1075 -1086.